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Abstract Chronic daily headache (CDH) is a debilitating disorder that becomes a treatment challenge in patients refractory to the treatment. We hereby report our experience with topiramate treatment in patients with refractory CDH. The study design was a prospective, protocol-based follow-up and retrospective analysis of headache diaries. We treated with topiramate at slowly increased moderate increments 11 CDH patients who were refractory to multiple previous treatments. Topiramate treatment was effective in 7 patients (64%). The treatment resulted in a 66% (median) decrease of the headache days per week and a significant decrease in headache severity, a reduction of the headache hours per day, and weekly analgesic consumption. These effects continued for an average follow-up of 8±4 months. The average effective dose was 100 mg/day. Slowly increasing the drug at moderate increments resulted in high tolerability of topiramate. We found topiramate to be an effective long-standing treatment option for patients with refractory CDH. Slow increments of the dosage contributed to high tolerability of the drug. cyclic antidepressants, serotonin specific reuptake inhibitors, non-steroidal anti-inflammatory drugs, analgesics, greater occipital nerve blocks and acupuncture, homeopathic or herbal treatments (used by some of the patients). We included males or females older than 18 years in whom the CDH was not due to medication overuse. The patients had an ophthalmological examination prior to the treatment and their weight was monitored. Data was collected through daily headache diaries. To improve tolerability, we started topiramate at a daily dose of 12.5 mg and increased the dosage biweekly by 12.5 mg, given bid. Weekly increments were further used if no adverse events were noted.
The Institutional Review Board approved the study according to the Helsinki rules and informed consent was obtained from each subject.
Results
Eleven patients with refractory CDH were treated with topiramate. The average age of the patients was 51±13 years (64% women). The median duration of the CDH at the time of the study entry was 5 years (range 2-25 years). Five patients had CDH of transformed migraine type. The rest had CDH of tension-type headache; among them one patient had recurrent surgeries for CSF shunting (initially performed for the treatment of hydrocephalus) and 2 patients had headache related to a post-traumatic stress disorder (Table 1) .
Topiramate successfully relieved headaches in 7 patients (64%). The number of headache days per week decreased by 66% (median; range 0%-96%); the headache hours per day were reduced by 50% (median; range 0-90%) and the severity of the headache lessened by 50% (median; range 0%-79%). In the 7 responders to topiramate the weekly analgesic consumption decreased by 74%±22% (average, range 50%-100%) ( Table 2 ). These effects continued for an average follow-up of 8±4 months (range 5-14 months).
Initial headache relief was noted after 5±4 weeks of treatment. The maximal daily dose of topiramate used by the patients who had headache relief was 100 mg (median; range 25-250 mg) ( Table 2 ). The 4 patients with no headache relief discontinued the treatment due to adverse effects (patients 10, 11; Table 2 ) or due to lack of efficacy (2 patients). The analgesic consumption of these patients did not change during the study follow-up.
Mild and tolerable adverse events of topiramate were reported by 7 patients (64%) and consisted of tiredness (2 patients), acral paraesthesias (2 patients) and difficulty in concentrating (2 patients) ( Table 2 ). Weight loss and weight gain (3 kg) were noted in 2 patients.
Discussion
In this study we found that topiramate was an effective treatment for patients with refractory CDH. Of theses patients, considered as 'treatment unresponsive', 7 patients (64%) gained with topiramate a significant reduction in the headache frequency, severity and analgesic consumption.
Patients with CDH do respond somewhat to various medical treatments and therefore the available population was limited, but represented the most challenging population in a headache clinic. Although this was an open Tr. Mig., transformed migraine; TTH, tension-type headache *Patient diagnosed with post-traumatic stress disorder **Patient had shunt insertion for the treatment of hydrocephalus uncontrolled study of a small population, the effect of the treatment that continued for 8±4 months is much longer than that expected for placebo. We therefore assume that it represents, in these particular our patients, a true effect of the treatment. Our results are in accordance with early observations on the usefulness of topiramate in transformed migraine [7] and we show here that the drug may be effectively used for other types of CDH. We increased the dose of topiramate gradually in small increments. Although there were some adverse events, we assume that this modality of drug augmentation enabled the high tolerability of topiramate during the long follow-up.
Conclusions
We found topiramate to be an effective, long-lasting preventive treatment option for patients with refractory CDH. Small increments of the dosage over many weeks contributed to high tolerability of the drug. 
